Literature DB >> 2202462

Bone marrow transplantation for acute lymphocytic leukemia utilizing total body irradiation followed by high doses of cytosine arabinoside: lack of superiority over cyclophosphamide-containing conditioning regimens.

W G Woods1, N K Ramsay, D J Weisdorf, R Haake, D A Vallera, T H Kim, L Lasky, M E Nesbit, B Bostrom, F Uckun.   

Abstract

The efficacy of a pre-bone marrow transplantation (BMT) preparative regimen consisting of single, high dose rate total body irradiation followed by 12 courses of high dose cytosine arabinoside (Ara-C) over 6 days with allogeneic or autologous rescue was studied in 68 consecutive patients with poor risk acute lymphocytic leukemia (ALL). Toxicity associated with the above preparative regimen included conjunctivitis in the majority of patients, severe gastrointestinal symptoms in seven patients (10%), skin desquamation in four patients (6%), and interstitial pneumonitis of unknown etiology in two patients (3%). One patient died from a 'capillary leak' syndrome that may have been attributable to Ara-C toxicity. With a follow-up of 1.1-4.3 years, the estimated survival is 21% (95% confidence interval, 10-32%), with a disease-free survival of 18% (8-28%) and an estimated relapse rate of 75% (62-88%) at 3 years. These results are not significantly different from overall outcome in 105 patients treated previously at this same institution with cyclophosphamide-containing preparative regimens (31% (22-40%) estimated survival, 29% (20-38%) disease-free survival, and an estimated relapse rate of 63% (52-74%) at 3 years), especially when results are stratified based on allogeneic versus autologous BMTs. Although efficacious for a minority of patients with poor risk ALL, a pre-BMT preparative regimen consisting of total body irradiation followed by high doses of Ara-C did not improve long-term survival over more conventional preparative regimens consisting of cyclophosphamide and total body irradiation. Future strategies may need to investigate novel approaches for reducing leukemic relapse rates in patients with ALL undergoing bone marrow transplantation.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2202462

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  6 in total

1.  Phase 1/2 trial of total marrow and lymph node irradiation to augment reduced-intensity transplantation for advanced hematologic malignancies.

Authors:  Joseph Rosenthal; Jeffrey Wong; Anthony Stein; Dajun Qian; Debbie Hitt; Hossameldin Naeem; Andrew Dagis; Sandra H Thomas; Stephen Forman
Journal:  Blood       Date:  2010-09-28       Impact factor: 22.113

2.  Efficiency of high-dose cytarabine added to CY/TBI in cord blood transplantation for myeloid malignancy.

Authors:  Yasuyuki Arai; June Takeda; Kazunari Aoki; Tadakazu Kondo; Satoshi Takahashi; Yasushi Onishi; Yukiyasu Ozawa; Nobuyuki Aotsuka; Yasuji Kouzai; Hirohisa Nakamae; Shuichi Ota; Chiaki Nakaseko; Hiroki Yamaguchi; Koji Kato; Yoshiko Atsuta; Akiyoshi Takami
Journal:  Blood       Date:  2015-06-01       Impact factor: 22.113

3.  Bendamustine with Total Body Irradiation Limits Murine Graft-versus-Host Disease in Part Through Effects on Myeloid-Derived Suppressor Cells.

Authors:  Jessica Stokes; Emely A Hoffman; Megan S Molina; Jelena Eremija; Nicolas Larmonier; Yi Zeng; Emmanuel Katsanis
Journal:  Biol Blood Marrow Transplant       Date:  2018-10-13       Impact factor: 5.742

4.  Fluid balance of pediatric hematopoietic stem cell transplant recipients and intensive care unit admission.

Authors:  Geneviève Benoit; Véronique Phan; Michel Duval; Martin Champagne; Catherine Litalien; Aicha Merouani
Journal:  Pediatr Nephrol       Date:  2006-11-23       Impact factor: 3.714

5.  Transplantation conditioning regimens and outcomes after allogeneic hematopoietic cell transplantation in children and adolescents with acute lymphoblastic leukemia.

Authors:  James Tracey; Mei-Jie Zhang; Elizabeth Thiel; Kathleen A Sobocinski; Mary Eapen
Journal:  Biol Blood Marrow Transplant       Date:  2012-10-03       Impact factor: 5.742

6.  Myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia: analysis of graft sources and long-term outcome.

Authors:  Michael B Tomblyn; Mukta Arora; K Scott Baker; Bruce R Blazar; Claudio G Brunstein; Linda J Burns; Todd E DeFor; Kathryn E Dusenbery; Dan S Kaufman; John H Kersey; Margaret L MacMillan; Philip B McGlave; Jeffrey S Miller; Paul J Orchard; Arne Slungaard; Marcie R Tomblyn; Gregory M Vercellotti; Michael R Verneris; John E Wagner; Daniel J Weisdorf
Journal:  J Clin Oncol       Date:  2009-07-06       Impact factor: 44.544

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.